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Editorial
Prospects for the future in the management of
carcinoma of the breast: The biological fall out from
clinical trials.
Large scale multicentre clinical trials are often stigmatized as contemporary
reincarnations of the brontosaurus (a lumbering slow-witted animal with a small brain
separated from its huge body by an attenuated neck). Like the brontosaurus many
predict that the clinical trial will become extinct to be replaced by a sleek, intelligent
and more efficient mechanism for approximating to the truth in clinical medicine. I
could, of course, argue that large numbers themselves have an intrinsic beauty, allowing
multiple sub group and regression analyses (Peto et al., 1976). I could also argue that
large numbers allow us to pick up modest but important differences in treatment
outcomes or alternatively minimize type II errors so as to provide us with statistical
powers of refutation (Frieman et al., 1978). However, that is not the purpose of this
paper. My intention in this discussion is to illustrate how the data originating from
clinical trials, if handled with an open mind plus a modicum of imagination, may serve
as the building blocks for new hypotheses, thus advancing the subject along the
hypothetico-deductive pathways of a science. This process I like to describe as the
"biological fall out" of clinical trials.
Trials oflocal therapy
Almost ten years ago I wrote a paper of a similar title looking at the "fall out" from
trials of loco-regional therapy for "early" breast cancer (Baum, 1975). In retrospect the
trials of that period were really addressing themselves to two different questions.
Firstly, would the use of radical radiotherapy provide the same degree of local control
and the same cure rates as radical surgery? In other words, was radiotherapy as
effective as surgery in ablating cancer from the regional nodes? The second set of trials
was asking a more interesting biological question concerning the relevance of the
regional nodes in the putative immunosurveillance of cancer. Thus procedures that left
the regional nodes intact were compared with surgical and radiotherapeutic techniques
aimed at total destruction of these nodes. Observed in toto we can now say (with
statistical confidence) that although the degree of local control varied directly with the
magnitude of the treatment field, no important differences in survival were detected
(Fisher, 1970).
Biological extrapolations from these data might suggest one of three conclusions: (a)
untreated lymph node metastases do not act as a source of tertiary spread; (b) the
immunosuppressive effects of radical surgery or regional radiotherapy are of no clinical
relevance; or (c) the metastasising capacity of involved nodes is balanced by the
immunosurveillance mediated in some way by the intact uninvolved lymph nodes.
Whatever the explanation these data supported the concept of "biological
predeterminism" and further analyses suggested that those patients with node positive
breast cancer were those most often predetermined to die (Fisher, 1970).118 EDITORIAL
As a result of this experience all but a few diehards amongst surgeons and
radiotherapists experienced a paradigm shift (conceptual revolution). The lymph node
status of the patient is now looked upon as an expression rather than a determinant of
prognosis (Devitt, 1965).
Trials ofadjuvant chemotherapy
If patients with "early" breast cancer and positive axillary nodes nearly always die
however perfect the loco-regional therapy then surely they carry occult micro-metastases
present at the time of diagnosis. As that must be the case then cure can only result
from the addition of an effective systemic therapy. Now our experience with advanced
breast cancer demonstrates an objective response rate of the order of 60% with
prolonged combination chemotherapy which is twice that expected with endocrine
therapy (Priestman et al., 1978). Ipso-facto node positive patients should be cured by
adjuvant systemic chemotherapy. So compelling were these arguments and so beautiful
the new hypothesis, many medical oncologists felt it unethical to do randomized trials
and like all inductivists (conceptual rationalists) soon found sufficient corroborative
evidence to satisfy themselves (Cooper et al., 1979). To my mind such individuals are as
guilty as those who uncritically accepted the Halstedian dogma seventy years ago and I
shall choose to ignore all the studies with historical rather than randomized controls [a
more detailed support of this scientific posture has recently been published (Baum,
1983)].
A recent review of the results of randomized controlled trials of adjuvant
chemotherapy has arrived at the following general conclusions (Howell & Morrison,
1983). (a) Whatever regime is used there is likely to be a delay in the time to first
relapse (increase in relapse-free survival). (b) Many trials have yet to show an
improvement in crude survival, but a generous interpretation of the data might suggest
that an increase in survival of about 10% could appear between 5 and 15 years after
starting treatment amongst certain subgroups. (c) Delay in time to first relapse appears
predominantly amongst premenopausal node positive patients. (d) Combination
chemotherapy is toxic and unpleasant and impairs the quality of life.
What therefore are the biological implications of these results?
Firstly, there is little doubt that the natural history of early breast cancer has been
perturbed, lending support to the deterministic model. Whether this perturbation will
translate itself into a therapeutic advantage remains to be seen.
Secondly, an intriguing difference has appeared between the behaviour of pre and
post menopausal women which derves some explanations.
One possible explanation that has found much support is that the effect of adjuvant
systemic chemotherapy is dose related (Bonadonna & Valagussa, 1981). Post
menopausal women seem incapable of tolerating the maximum (?optimum) doses
prescribed. This suggestion requires further exploration with trials of high dose versus
low dose chemotherapy. To accept the suggestion without such prospective studies is to
be guilty of a tautology. Yet at the same time if older women were incapable of
tolerating high dose chemotherapy then this is an inherent defect of the treatment,
unless you are prepared to push the drugs beyond the tolerance of the patient - surely a
dangerous and inhumane policy.
An alternative explanation for this differential effect might be that the cytotoxic
drugs are mediating their effect via a chemical castration. This hypothesis has alreadyEDITORIAL 119
won some support following studies of ovarian and pituitary function in women
receiving adjuvant chemotherapy (Rose & Davis, 1977).
It follows, therefore, that to test this hypothesis generated by the trials of adjuvant
chemotherapy one should conduct trials of adjuvant endocrine therapy.
Trials ofadjuvant endocrine therapy
Trials of adjuvant endocrine therapy are not new but have suffered in the past from
inadequate sample size leaving uncertainty as to its potential benefit. The subject has
recently been reviewed with the conclusion that most previous trials have demonstrated
a prolonged disease-free interval, at the expense of minimal toxicity, but no effect on
crude survival (Baum & Berstock, 1982).
For the purpose of this paper I wish to concentrate on one particular trial which at
least has an adequate sample size although lacking in maturity. The Nolvadex Adjuvant
Trial Organisation (N.A.T.O.) launched a study in 1977 to investigate whether the
antioestrogen tamoxifen (Nolvadex) would have any benefit for women undergoing
mastectomy for early breast cancer. Approximately 1,300 patients were recruited over a
period of two and a half years. These consisted of premenopausal node positive cases
and post menopausal node positive and negative cases. Following local therapy women
were randomized to a group receiving tamoxifen 10mg twice daily for two years or an
untreated control group. A secondary hypothesis suggested that the women most likely
to benefit were those whose primary tumour was rich in oestradiol receptor (E2R)
content. Therefore as a parallel study attempts were made to collect samples of the
tumours from all patients entering the trial. However, for logistic reasons this was only
possible in about 50% of the cases. The published data have demonstrated a
significantly prolonged disease-free interval in the treated group as a whole. Suprisingly
Cox's multivariant regression analysis has failed to demonstrate any interaction between
the treatment and sub-groups divided according to menopausal, nodal or E2R status
(Nolvadex Adjuvant Trial Organisation, 1983).
More recently a letter appeared in the Lancet reporting that this prolongation of
disease-free survival had been translated into an improvement in actual survival
amongst the treated group at the relatively short maximum follow-up of five years
(Baum et al., 1983).
It is too early to make therapeutic recommendations and furthermore it is
conceivable that on withdrawal of tamoxifen the treated group will demonstrate an
accelerated death rate if the drug is not curing the disease but merely providing
temporary control. Nevertheless if these data are confirmed by other trials of a similar
design (and early reports suggest this may be the case) (Senanayake, 1983, personal
communication), then we already have food for thought which can direct future
research.
Biologicalfall outfrom trials ofadjuvant tamoxifen
Let us consider four possible outcomes from the tamoxifen trials.
(1) Adjuvant tamoxifen increases survival long term.
(2) Adjuvant tamoxifen improves actual survival or the disease-free interval in the
short term but on withdrawal the life table curves dip to meet the control group.120 EDITORIAL
(3). The oestradiol receptor status of the primary tumour is a predictor of those
patients responding to tamoxifen.
(4) The E2R status of the primary tumour is unrelated to response to adjuvant
tamoxifen but remains a prognostic indicator.
Outcome (1) would suggest that the antioestrogen has a tumoricidal capacity for the
putative micrometastases present at the time of diagnosis. This in itself would be
interesting suggesting that subclinical tumour deposits are biologically different from
overt metastatic disease.
Outcomes (2) and (3) would be very much as predicted reinforcing the prejudice that
occult metastases behave in the same manner as the overt disease. The result might be
considered of therapeutic value because of the lack of toxicity of tamoxifen but
biologically the fall out would be small and provide no useful direction for future
research with one exception. If tamoxifen can control the disease in the short term after
two years exposure, then perhaps dosage for life might increase the therapeutic gain
(Insulin and diabetes might serve as a relevant analogy).
Outcome (4), which is already hinted at on preliminary data analysis, would be the
most interesting and demanding of biological interpretation. As such an outcome fails
to reinforce popular prejudice there will naturally be the temptation to ignore or reject
the data. It has already been suggested that the measurements of E2R in a multicentre
trial with interlaboratory variation will produce many false negative results. This indeed
may be the case but it remains unquestionable that their assays have told us something
of biological relevance about the primary cancers in this study, as there is a powerful
correlation between the E2R status and prognosis irrespective of primary or adjuvant
therapy (Wilson, 1983).
For the rest of this article, therefore, let us see if an hypothesis can be reconstructed
from debris of shattered illusions.
Does tamoxifen act via an alternative pathway?
Tamoxifen is thought to exert its effect via the oestradiol receptor (E2R) and there is
little doubt that this is the major pathway mediating its anti-tumour effect in advanced
breast cancer (Patterson et al., 1982). Paradoxically, however, the oestradiol receptor
status of the primary cancer does not appear to predict whether or not adjuvant
tamoxifen will prolong the disease-free interval after mastectomy (Nolvadex Adjuvant
Trial Organisation, 1983). This raises the question as to whether tamoxifen may exert
some of its effect by another pathway (Patterson et al., 1982). More recently a
ubiquitous tamoxifen-binding protein has been discovered in tissues having no
detectable E2R (Kon, 1983). Perhaps tamoxifen binding to this cytosolic protein
intereferes with growth factor activity. Furthermore, tamoxifen can inhibit
prostaglandin synthesis in vitro, an effect that might be a predictable property of an
anti-growth factor (Ritchie, 1978). If tamoxifen should turn out to have anti-growth
factor (GF) capacity, then this in itself might suggest that E2R status is merely an
epiphenomenon of cellular differentiation indirectly reflecting the rate of inappropriate
GF production, serving as a prognostic indicator rather than as an expression of
endocrine sensitivity.
Further support for the idea that E2R is an indirect expression of the rate of growth
factor production comes from the following data:EDITORIAL 121
(1) ER2 positive cancers are predominantly well differentiated on histological grading
(Fisher et al., 1980) and carry a better prognosis than E2R negative tumours.
(2) E2R status of breast cancers is inversely correlated with the rate of replication of
cells in vitro (Meyer et al., 1977).
(3) Growth factors are known to potently attract monocytes (Waterfield et al., 1983).
A monocytosis is a recognized response to an actively growing tumour (Baum &
Fisher, 1972) and a heavy stromal round cell infiltrate correlates with a negative
E2R status (Steele, 1983).
(4) Another of the early cellular responses to growth factors is the accumulation of
cyclic AMP mediated by the synthesis of E-type prostaglandins (Coughlin et al.,
1980). PGE2 is found in many tumours and has been suggested as a prognostic
variable (Bennett et al., 1983) which is directly correlated with histological grade
(Bishop, et al., 1980) which, as already described, is inversely correlated with E2R
content.
Thus at one extreme we might have a cancer with a very high rate of production of
GF where the rate of replication and protein synthesis does not allow sufficient time or
amino acids for the assembly of E2R, whilst at the other extreme of slow GF release
E2R assembly proceeds to completion. This then raises the intriguing probability that
tamoxifen may "slow" the tumour via an anti-GF pathway until E2R is reassembled so
that it can exhibit a secondary effect along the classic pathway.
All the predictions of this hypothesis are eminently testable, almost guaranteeing its
refutation or elaboration with time!
Department of Surgery, M. Baum
Kings College Hospital, London.
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